RxDoctor Payments Data

Hussein Ajrouche, MD

Internal Medicine · Dearborn, MINPI 1073675427

Payments from drug & device makers

$7,381in general payments, 2019–2025

Across 444 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$878
  • AbbVie$729
  • AstraZeneca$722
  • Ironwood Pharmaceuticals, Inc$628
  • Pfizer$504
  • Boehringer Ingelheim$414
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,375100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,381 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$169,723
Medicare patients
320
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin162$119,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter132$81,532
EliquisApixaban118$80,068
JanuviaSitagliptin Phosphate82$58,007
LinzessLinaclotide103$57,942
TrulicityDulaglutide45$48,989
FarxigaDapagliflozin Propanediol60$40,530
EntrestoSacubitril/Valsartan40$39,559
OzempicSemaglutide36$36,998
TradjentaLinagliptin45$25,075
MultaqDronedarone Hcl22$17,120
TrintellixVortioxetine Hydrobromide33$15,492
VraylarCariprazine Hcl11$15,405
XareltoRivaroxaban24$15,161
Breo ElliptaFluticasone/Vilanterol34$13,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$414$151,893220 claims
GSKTrelegy Ellipta, Breo Ellipta$878$95,092166 claims
PfizerEliquis$504$80,068118 claims
AbbVieLinzess, Vraylar$729$73,347114 claims
AstraZenecaFarxiga, Brilinta, Symbicort$722$58,056103 claims
MerckJanuvia$362$58,00782 claims
Lilly USA, LLCTrulicity$328$48,98945 claims
NovartisEntresto$191$39,55940 claims
Novo NordiskOzempic$219$36,99836 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$110$15,49233 claims
Johnson & JohnsonXarelto$16$15,16124 claims
Sumitomo Pharma America, Inc.Gemtesa$234$10,93223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →